| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The PHQ-9: validity of a brief depression severity measure.
|
J Gen Intern Med
|
2001
|
76.04
|
|
2
|
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
|
Lancet
|
2004
|
42.12
|
|
3
|
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.
|
Lancet
|
2006
|
37.83
|
|
4
|
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
|
Lancet
|
2005
|
32.41
|
|
5
|
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
|
BMJ
|
2002
|
20.22
|
|
6
|
A strategy to reduce cardiovascular disease by more than 80%.
|
BMJ
|
2003
|
19.05
|
|
7
|
Socioeconomic inequalities in health in 22 European countries.
|
N Engl J Med
|
2008
|
14.36
|
|
8
|
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
|
Lancet
|
2009
|
13.64
|
|
9
|
Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence.
|
Arch Intern Med
|
2000
|
12.83
|
|
10
|
Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research.
|
Med Care
|
2004
|
12.32
|
|
11
|
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
|
BMJ
|
2003
|
11.21
|
|
12
|
Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial.
|
JAMA
|
2003
|
10.59
|
|
13
|
Estimates of global mortality attributable to smoking in 2000.
|
Lancet
|
2003
|
10.52
|
|
14
|
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.
|
Circulation
|
2006
|
8.01
|
|
15
|
Predictors of hospital mortality in the global registry of acute coronary events.
|
Arch Intern Med
|
2003
|
7.25
|
|
16
|
Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.
|
JAMA
|
2007
|
7.11
|
|
17
|
Social support and patient adherence to medical treatment: a meta-analysis.
|
Health Psychol
|
2004
|
6.47
|
|
18
|
Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use.
|
Lancet
|
2007
|
6.45
|
|
19
|
Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.
|
Lancet
|
2001
|
6.38
|
|
20
|
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.
|
Lancet
|
2009
|
5.84
|
|
21
|
The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.
|
Bull World Health Organ
|
2007
|
4.48
|
|
22
|
Impact of medication therapy discontinuation on mortality after myocardial infarction.
|
Arch Intern Med
|
2006
|
4.44
|
|
23
|
Fixed-dose combinations improve medication compliance: a meta-analysis.
|
Am J Med
|
2007
|
4.20
|
|
24
|
Prevention of chronic diseases: a call to action.
|
Lancet
|
2007
|
3.87
|
|
25
|
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
|
Lancet
|
2006
|
3.43
|
|
26
|
Scaling up interventions for chronic disease prevention: the evidence.
|
Lancet
|
2007
|
3.24
|
|
27
|
Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications.
|
Circulation
|
2006
|
3.10
|
|
28
|
WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE).
|
Bull World Health Organ
|
2005
|
3.09
|
|
29
|
Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes.
|
Circulation
|
2004
|
2.90
|
|
30
|
Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction.
|
Circulation
|
2008
|
2.76
|
|
31
|
Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action.
|
Public Health Nutr
|
2002
|
2.34
|
|
32
|
Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
|
Arch Intern Med
|
2006
|
2.28
|
|
33
|
Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study.
|
Arch Intern Med
|
2005
|
2.28
|
|
34
|
A polypill strategy to improve adherence: results from the FOCUS project.
|
J Am Coll Cardiol
|
2014
|
1.72
|
|
35
|
The preventive polypill--much promise, insufficient evidence.
|
N Engl J Med
|
2007
|
1.58
|
|
36
|
[Reduction in acute myocardial infarction mortality over a five-year period].
|
Rev Esp Cardiol
|
2006
|
1.57
|
|
37
|
Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996 2005.
|
Eur Heart J
|
2007
|
1.49
|
|
38
|
Polypill holds promise for people with chronic disease.
|
Bull World Health Organ
|
2006
|
1.48
|
|
39
|
Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa.
|
Heart
|
2008
|
1.26
|
|
40
|
Impact of fixed-dose combination drugs on adherence to prescription medications.
|
J Gen Intern Med
|
2008
|
1.23
|
|
41
|
Combination pharmacotherapy for cardiovascular disease.
|
Ann Intern Med
|
2005
|
1.14
|
|
42
|
Benefits, challenges, and registerability of the polypill.
|
Eur Heart J
|
2006
|
1.07
|
|
43
|
Global preventive policies. Strategies at European and worldwide level.
|
Rev Esp Cardiol
|
2008
|
1.07
|
|
44
|
Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.
|
Am J Cardiovasc Drugs
|
2008
|
1.06
|
|
45
|
Poverty and human development: the global implications of cardiovascular disease.
|
Circulation
|
2007
|
1.00
|
|
46
|
Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry.
|
Am Heart J
|
2005
|
0.95
|
|
47
|
Tapping the potential of fixed-dose combinations.
|
Nat Rev Drug Discov
|
2007
|
0.87
|
|
48
|
The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.
|
Am Heart J
|
2011
|
0.87
|
|
49
|
A polypill for secondary prevention: time to move from intellectual debate to action.
|
Nat Clin Pract Cardiovasc Med
|
2007
|
0.86
|
|
50
|
Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke.
|
Am J Cardiol
|
2007
|
0.80
|
|
51
|
Highlights of the 2007 scientific sessions of the European Society of Cardiology Vienna, Austria, September 1-5, 2007.
|
J Am Coll Cardiol
|
2007
|
0.77
|
|
52
|
Is a multidrug regimen cost-effective for the prevention of cardiovascular disease in resource-poor countries?
|
Nat Clin Pract Cardiovasc Med
|
2007
|
0.75
|
|
53
|
[Risk stratification in acute coronary syndromes: an unresolved issue].
|
Rev Esp Cardiol
|
2007
|
0.75
|